Clinical consequences of screening for prostate cancer: 15 Years follow-up of a randomised controlled trial in Sweden

European Urology

Volumn 46, Issue 6, 2004, Pages 717-724

  Sandblom, Gabriel ^a   Varenhorst, Eberhard ^b   Löfman, Owe ^c   Rosell, Johan ^d   Carlsson, Per ^d  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b Department of Urology and Surgery   (Sweden)

^c LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^d LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Digital rectal examination; Prostate cancer; Prostate Specific Antigen; Screening; Survival; Treatment; Tumour stage

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER EPIDEMIOLOGY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER REGISTRY; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL EXAMINATION; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; FEASIBILITY STUDY; FOLLOW UP; GENERAL PRACTICE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 8444233301     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2004.08.011     Document Type: Article

References (17)

1. J. Ferlay, F. Bray, P. Pisani, and D.M. Parkin GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide, version 1.0. IARC CancerBase 5th ed. 2001 IARC Press Lyon
2. J.K. Gohagan, P.C. Prorok, B.S. Kramer, R.B. Hayes, and J.E. Cornett The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial of the National Cancer Institute Cancer 75 1995 1869 1873
3. Schröder FH, Kranse R, Riebergen J, Hoedemaeke R, Krikels W. The European Randomized Study of Screening for Prostate Cancer (ERSPC): an update. Members of the ERSPC, Section Rotterdam. Eur Urol 1999;35:539-43.
4. K.V. Pedersen, P. Carlsson, E. Varenhorst, O. Löfman, and K. Berglund Screening for carcinoma of the prostate by digital rectal examination in a randomly selected population Br Med J 300 1990 1041 1044
5. E. Varenhorst, K. Berglund, O. Löfman, and K.V. Pedersen Interobserver variation in the assessment of prostate by digital rectal examination by urologist and general practitioner. Analysis using kappa-statistics Br J Urol. 72 1993 173 176
6. P. Carlsson, K.V. Pedersen, and E. Varenhorst Costs and benefits of early detection of prostatic cancer Health Policy 16 1990 241 253
7. Mattsson B. The completeness of registration in the Swedish Cancer Registry. Stockholm: Stat Rep HS; Report No 15, 1977.
8. G. Sandblom, M. Dufmats, M. Olsson, and E. Varenhorst Validity of a population-based cancer register in Sweden - an assessment of data reproducibility in the South-East Region Prostate Cancer Register Scand J Urol Nephrol. 37 2003 112 119
9. UICC (Union internationale Contre le Cancer) TNM Classification of Malignant Tumours 5th ed. 1997 International Union Against Cancer Geneva (Switzerland)
10. G. Aus, K. Nordenskjöld, D. Robinson, J. Rosell, and E. Varenhorst Progostic factors and survival in node-positive (N1) prostate cancer - a prospective study based on data from a Swedish population-based cohort European Urology 43 2003 627 631
11. J.I. Epstein, M.J. Carmichael, G. Pizov, and P.C. Walsh Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term follow-up J Urol. 150 1993 135 141
12. H.J. de Koning, A. Auvinen, and A. Berenguer Sanchez Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial Int J Cancer 97 2 2002 237 244
13. B.-M. Ljung, R. Cherrie, and J.J. Kaufman Fine needle aspiration biopsy of the prostate gland: a study of 103 cases with histological follow up J Urol 135 1986 955 958
14. The National Board of Health and Welfare. Yearbook of Health and Medical Care 2001, Statistics - Health and Medical Care. Stockholm 2001.
15. I.W. van der Cruijsen-Koeter, T.H. van der Kwast, and F.H. Schröder Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam J Natl Cancer Inst. 95 19 2003 1462 1466
16. R. Etzioni, DF. Penson, J.M. Legler, J.M. Legler, D.T. Tommaso, and R. Boer Overdiagnosis due to prostate-specific antigen screening: lessons from US prostate cancer incidence trends J Natl Cancer Inst 94 2002 981 990
17. G. Draisma, R. Boer, S.J. Otto, I.W. van der Cruijsen, R.A.M. Damhuis, and F.H. Schröder Lead times and overdetection due to prostate-specific antigen screening: estimates from the European randomized study of screening for prostate cancer J Natl Cancer Inst. 95 2003 868 878